Source:http://linkedlifedata.com/resource/pubmed/id/16044276
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2005-10-19
|
| pubmed:abstractText |
The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) of anthracycline ( P <0.05). During the follow-up period, the fractional shortening (FS) declined in the no-dexrazoxane group only in the 8th year and was significantly lower compared to the dexrazoxane group ( P <0.05). The pathological decrease in FS was present in 24% of patients; 41% in the no-dexrazoxane and 17% in the dexrazoxane groups, respectively ( P <0.05). DSE demonstrated lower rest EF and cardiac index (CI) in the no-dexrazoxane group ( P <0.05); however, neither the response of EF and CI to the stress echocardiography nor the exercise tolerance significantly differed between sub-groups. A higher number of patients in the dexrazoxane group had very good exercise tolerance (ET) >3 Watts/kg ( P <0.05) and a lower number responded with a decreased ET <2 Watts/kg ( P <0.05) compared to the no-dexrazoxane group. CONCLUSION: Dexrazoxane seems to reduce the risk of late subclinical cardiotoxicity. Dexrazoxane-treated patients revealed better exercise tolerance; however the haemodynamic response to the stress was no different in both sub-groups.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cardiovascular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Razoxane
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0340-6199
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
164
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
678-84
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16044276-Adolescent,
pubmed-meshheading:16044276-Anthracyclines,
pubmed-meshheading:16044276-Antineoplastic Agents,
pubmed-meshheading:16044276-Blood Pressure,
pubmed-meshheading:16044276-Body Mass Index,
pubmed-meshheading:16044276-Cardiovascular Agents,
pubmed-meshheading:16044276-Child,
pubmed-meshheading:16044276-Child, Preschool,
pubmed-meshheading:16044276-Czech Republic,
pubmed-meshheading:16044276-Daunorubicin,
pubmed-meshheading:16044276-Dose-Response Relationship, Drug,
pubmed-meshheading:16044276-Doxorubicin,
pubmed-meshheading:16044276-Echocardiography, Stress,
pubmed-meshheading:16044276-Female,
pubmed-meshheading:16044276-Follow-Up Studies,
pubmed-meshheading:16044276-Heart,
pubmed-meshheading:16044276-Heart Rate,
pubmed-meshheading:16044276-Humans,
pubmed-meshheading:16044276-Infant,
pubmed-meshheading:16044276-Male,
pubmed-meshheading:16044276-Neoplasms,
pubmed-meshheading:16044276-Prospective Studies,
pubmed-meshheading:16044276-Razoxane,
pubmed-meshheading:16044276-Time Factors,
pubmed-meshheading:16044276-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
|
| pubmed:affiliation |
Department of Cardiology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic. lelbl@fnbrno.cz
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|